NASDAQ$INBX

Inhibrx Biosciences Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Headline financials

Total Revenue

$0.00

Previous: $17K-100.0%
EPS (adj)

-$1.44

Previous: -$1.12-28.6%
Capital Expenditures

-$1.12M

Previous: -$23K-4765.2%
Free Cash Flow

-$64.2M

Previous: -$40M-60.6%
Net Income

-$78.7M

Previous: -$48.9M-60.9%
Operating Income

-$73.8M

Previous: -$43.8M-68.7%
Gross Profit

-$360K

No prior period
Cash & Equivalents

$252M

No prior period
Total Assets

$289M

No prior period
R&D Expense

$63.6M

Previous: $37.1M+71.2%

Revenue & EPS history

Inhibrx Biosciences Inc · Revenue · Quarterly

$0

Q1 2024-100%vs Q1 2023
Beat estimate in 2 of 6 quarters(33%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 7 quarterly earnings reports

Historical avg

-2.2%

Avg return

Earnings day

-0.4%

Avg return

5 days after

+1.4%

Avg return

30 days after

36%

8 / 22 earnings

Positive

+8.4%

Q2 2021

Best reaction

-17.4%

Q2 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+0.2%-13.9%-33.7%
Q3 2025+5.7%+10.1%+6.6%
Q2 2025+1.9%-2.4%+16.8%
Q1 2025-1.9%-1.3%+9.9%
Q4 2024-0.7%+1.8%-18.7%
Q3 2024-10.5%-7.5%-5.4%
Q2 2024+0.4%+10.8%+34.0%
Q1 2024-0.4%
Q4 2023-7.4%
Q3 2023+0.1%
Q2 2023-17.4%
Q1 2023-2.5%
Q4 2022-0.8%
Q3 2022-4.2%
Q2 2022+7.4%
Q1 2022-7.1%
Q4 2021-1.6%
Q3 2021-3.5%
Q2 2021+8.4%
Q1 2021+3.7%
Q4 2020-13.6%
Q3 2020-4.5%
Q2 2020
Q1 2020
Q4 2019
Q3 2019
Q2 2019
Q1 2019
Q4 2018
Q2 2018
Q1 2018
Q4 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro